MetLife Investment Management’s Inovio Pharmaceuticals INO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-15,167
| Closed | -$87.7K | – | 2833 |
|
|
2024
Q3 | $87.7K | Buy |
15,167
+8,546
| +129% | +$49.4K | ﹤0.01% | 2674 |
|
|
2024
Q2 | $53.5K | Buy |
+6,621
| New | +$53.5K | ﹤0.01% | 2750 |
|
|
2023
Q2 | – | Sell |
-10,547
| Closed | -$104K | – | 2966 |
|
|
2023
Q1 | $104K | Buy |
10,547
+2,473
| +31% | +$24.3K | ﹤0.01% | 2535 |
|
|
2022
Q4 | $151K | Sell |
8,074
-1,837
| -19% | -$34.4K | ﹤0.01% | 2414 |
|
|
2022
Q3 | $205K | Buy |
9,911
+4,328
| +78% | +$89.6K | ﹤0.01% | 2281 |
|
|
2022
Q2 | $116K | Sell |
5,583
-3,947
| -41% | -$81.9K | ﹤0.01% | 2651 |
|
|
2022
Q1 | $411K | Buy |
9,530
+3,441
| +57% | +$148K | ﹤0.01% | 1893 |
|
|
2021
Q4 | $365K | Buy |
6,089
+1,077
| +21% | +$64.5K | ﹤0.01% | 1675 |
|
|
2021
Q3 | $431K | Sell |
5,012
-883
| -15% | -$75.9K | ﹤0.01% | 1606 |
|
|
2021
Q2 | $656K | Hold |
5,895
| – | – | 0.01% | 1415 |
|
|
2021
Q1 | $656K | Buy |
5,895
+368
| +7% | +$41K | 0.01% | 1373 |
|
|
2020
Q4 | $587K | Hold |
5,527
| – | – | 0.01% | 1405 |
|
|
2020
Q3 | $769K | Buy |
5,527
+253
| +5% | +$35.2K | 0.01% | 1160 |
|
|
2020
Q2 | $1.71M | Buy |
5,274
+1,401
| +36% | +$453K | 0.02% | 791 |
|
|
2020
Q1 | $346K | Hold |
3,873
| – | – | ﹤0.01% | 1416 |
|
|
2019
Q4 | $153K | Buy |
+3,873
| New | +$153K | ﹤0.01% | 2123 |
|
|
2019
Q3 | – | Sell |
-3,025
| Closed | -$107K | – | 2360 |
|
|
2019
Q2 | $107K | Hold |
3,025
| – | – | ﹤0.01% | 2357 |
|
|
2019
Q1 | $135K | Hold |
3,025
| – | – | ﹤0.01% | 2192 |
|
|
2018
Q4 | $145K | Hold |
3,025
| – | – | ﹤0.01% | 2095 |
|
|
2018
Q3 | $202K | Hold |
3,025
| – | – | ﹤0.01% | 2074 |
|
|
2018
Q2 | $142K | Hold |
3,025
| – | – | ﹤0.01% | 2087 |
|
|
2018
Q1 | $171K | Hold |
3,025
| – | – | ﹤0.01% | 1969 |
|
|
2017
Q4 | $150K | Buy |
+3,025
| New | +$150K | ﹤0.01% | 2067 |
|